October 1, 2026Circulation Arrhythmia and Electrophysiology
Atrial Fibrillation Ablation Effectiveness End Points, Safety End Points, and Trial Design: Academic Research Consortium Initiative Endorsed by the Heart Rhythm Society
Why the study?
Trial design and safety and effectiveness end points for pivotal clinical trials evaluating catheter ablation for symptomatic atrial fibrillation require reexamination to provide meaningful data for regulatory decision-making.
Population
Patients with symptomatic paroxysmal, persistent, or longstanding persistent atrial fibrillation
Design
Consensus initiative with international experts and working groups endorsed by Heart Rhythm Society
Authors
Discussion
Loading...
Member takes
Overview
Updates AF ablation trial endpoints and designs for regulatory use; extends prior consensus across paroxysmal to longstanding persistent populations.
Key Points
- Reexamine trial design and establish standardized safety and effectiveness endpoints for pivotal clinical trials evaluating catheter ablation in symptomatic atrial fibrillation to guide regulatory decision-making.
- Convened international expert working groups from July 2024 to February 2026 addressing effectiveness endpoints, safety endpoints, and trial designs/report forms.
- Integrated multigroup stakeholder collaboration comprising the FDA Center for Devices and Radiological Health, Heart Rhythm Society leadership, industry representatives, and a patient advocate.
- Established unified consensus definitions and criteria for primary safety and effectiveness endpoints in atrial fibrillation catheter ablation trials.
- Generated standardized trial design frameworks and reporting forms tailored to evaluate therapies across paroxysmal, persistent, and longstanding persistent atrial fibrillation populations.
Structured PICO
P
Population
Patients with symptomatic paroxysmal, persistent, or longstanding persistent atrial fibrillation (target population for the proposed trial designs)
I
Intervention
Catheter ablation for the treatment of symptomatic atrial fibrillation (target intervention for the proposed trial designs)
This AFA-ARC consensus document provides updated standards for trial design and endpoints in pivotal clinical trials evaluating catheter ablation for atrial fibrillation to support regulatory decision-making.
Cite This Study
Wang et al. (2026) conducted a review in Symptomatic paroxysmal, persistent, or longstanding persistent atrial fibrillation. Catheter ablation was evaluated on Revised effectiveness and safety end points, study design, and report forms. The AFA-ARC initiative proposed revised effectiveness and safety end points, study design, and report forms for pivotal clinical trials evaluating catheter ablation of atrial fibrillation.